Key facts
- It has raised $6.7M; the latest was Early Stage VC in Feb 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for EPOK Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for EPOK Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EPOK Therapeutics
Operator of a clinical-stage biopharmaceutical company intended to develop novel antibody-based therapeutics for the treatment of metabolic diseases. The company's lead product candidate is an antibody-drug conjugate targeting the EPO receptor with several recombinant versions of human erythropoietin, enabling medical professionals to treat anemia associated with chronic kidney disease (CKD).
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2023
- Employees
- 5
- Website
- epoktherapeutics.com/
- Ownership
- Privately Held (backing)
EPOK Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EPOK Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EPOK Therapeutics in its N-PORT filings yet. We sweep new filings monthly.